Histone-lysine N-methyltransferase EHMT2 (G9a) inhibition mitigates tumorigenicity in Myc-driven liver cancer.

MLA

Thng, Dexter Kai Hao, et al. “Histone-Lysine N-Methyltransferase EHMT2 (G9a) Inhibition Mitigates Tumorigenicity in Myc-Driven Liver Cancer.” Molecular Oncology, vol. 17, no. 11, Nov. 2023, pp. 2275–94. EBSCOhost, https://doi.org/10.1002/1878-0261.13417.

APA

Thng, D. K. H., Hooi, L., Toh, C. C. M., Lim, J. J., Rajagopalan, D., Syariff, I. Q. C., Tan, Z. M., Rashid, M. B. M. A., Zhou, L., Kow, A. W. C., Bonney, G. K., Goh, B. K. P., Kam, J. H., Jha, S., Dan, Y. Y., Chow, P. K. H., Toh, T. B., & Chow, E. K.-H. (2023). Histone-lysine N-methyltransferase EHMT2 (G9a) inhibition mitigates tumorigenicity in Myc-driven liver cancer. Molecular Oncology, 17(11), 2275–2294. https://doi.org/10.1002/1878-0261.13417

Chicago

Thng, Dexter Kai Hao, Lissa Hooi, Clarissa Chin Min Toh, Jhin Jieh Lim, Deepa Rajagopalan, Imran Qamar Charles Syariff, Zher Min Tan, et al. 2023. “Histone-Lysine N-Methyltransferase EHMT2 (G9a) Inhibition Mitigates Tumorigenicity in Myc-Driven Liver Cancer.” Molecular Oncology 17 (11): 2275–94. doi:10.1002/1878-0261.13417.